Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation of CDK4/6 inhibitors after durable disease control in metastatic HR-positive, HER2-negative breast cancer
2023-504141-31-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib, palbociclib, ribociclib, anastrozole, letrozole and 2 more in breast cancer (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Progression-free survival rate at 12 months after randomization. Planned start Nov 2023; status: authorised.
02
Drugs
abemaciclibpalbociclibribociclibanastrozoleletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-504141-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504141-31-00.